Back to top
more

Kymera Therapeutics (KYMR)

(Delayed Data from NSDQ)

$43.66 USD

43.66
379,788

+0.70 (1.63%)

Updated Aug 4, 2025 04:00 PM ET

After-Market: $43.66 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (143 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Myriad Genetics (MYGN) Q2 Earnings and Revenues Top Estimates

by Zacks Equity Research

Myriad (MYGN) delivered earnings and revenue surprises of 100% and 6.67%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Vericel Corporation (VCEL) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Vericel Corporation (VCEL) delivered earnings and revenue surprises of -46.15% and 3.27%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Analysts Estimate Kymera Therapeutics, Inc. (KYMR) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Kymera Therapeutics, Inc. (KYMR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Kymera Therapeutics, Inc. (KYMR) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Kymera Therapeutics, Inc. (KYMR) delivered earnings and revenue surprises of -5.97% and 44.58%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Kymera Therapeutics, Inc. (KYMR) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

Kymera Therapeutics, Inc. (KYMR) delivered earnings and revenue surprises of -83.33% and 27.78%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Exelixis (EXEL) Tops Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Exelixis (EXEL) delivered earnings and revenue surprises of 314.29% and 26.31%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Kymera Therapeutics, Inc. (KYMR) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Kymera Therapeutics, Inc. (KYMR) delivered earnings and revenue surprises of -64.71% and 0.78%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Kymera Therapeutics, Inc. (KYMR) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

by Zacks Equity Research

Kymera Therapeutics, Inc. (KYMR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

5 Reasons to Buy Vertex Pharmaceuticals (VRTX) Stock Now

by Zacks Equity Research

New reimbursement agreements in ex-U.S. markets and label expansions to younger age groups should drive sales of Vertex's (VRTX) cystic fibrosis drug, Trikafta sales higher.

Zacks Equity Research

Vertex (VRTX) Inks New Deal for CRISPR Gene-Editing Rights

by Zacks Equity Research

Vertex (VRTX) collaboration with Arbor will support discovery & development of new treatment options for serious diseases using the latter's CRISPR technology.

Zacks Equity Research

Company News for Jun 29, 2021

by Zacks Equity Research

Companies in the news are: NTLA, AVXL, MNKD, KYMR

Zacks Equity Research

Vertex (VRTX) Inks Deal with Skyhawk for Serious Diseases

by Zacks Equity Research

Vertex (VRTX) signs a licensing agreement with privately held company Skyhawk Therapeutics to discover novel small molecules that modulate RNA splicing for treating serious diseases.